Introduction
Multiple nicotinic receptors (nAChRs), including the α4β2* and α6β2* subtypes, are present in striatum (Gotti et al., 2006c; Wonnacott et al., 2005) , a region of particular relevance to Parkinson's disease. This neurodegenerative movement disorder is characterized by declines in dopaminergic cell bodies in the substantia nigra and nerve terminals in the striatum (Davidson et al., 1971; Hornykiewicz, 1975; Olanow, 2004; Samii et al., 2004; Savitt et al., 2006) . Since nAChRs are present on striatal dopaminergic terminals, these receptors are correspondingly decreased in experimental models of nigrostriatal damage and Parkinson's disease (Quik, 2004) .
This includes the α6β2* nAChR that is localized exclusively on nigrostriatal dopamine neurons and also the α4β2* receptor present both on dopamine nerve terminals and other striatal neurons (Champtiaux et al., 2003; Gotti et al., 2006a; Quik et al., 2005; Salminen et al., 2005; Zoli et al., 2002) . Declines in α6β2* nAChRs with nigrostriatal damage closely parallel losses in dopaminergic markers (Quik et al., 2001) . In contrast, α4β2* receptors are also decreased but only with severe nigrostriatal damage (Kulak et al., 2002a) . These findings raised the question whether nerve terminals expressing α6β2* nAChRs are more susceptible to nigrostriatal degeneration, suggesting these receptors represent a marker for such dopaminergic neurons.
However, no conclusive relationship has yet been observed using existing nAChR ligands.
Radioligands currently available to study striatal α4β2* and α6β2* nAChR expression include; epibatidine that labels α2*-α6* nAChRs, A85380 that identifies β2* nAChRs, and α-conotoxin MII (α-CtxMII) that interacts with α3β2* and α6β2* nAChRs (Gotti and Clementi, 2004; Quik, 2004; Quik and McIntosh, 2006) . Since mice and rats do not express α3β2* nAChRs in striatum, 125 I-α-CtxMII has proved an excellent tool to label α6β2* nAChRs in monkey and human striatum are more complex because of the presence of both the α6β2* and α3β2* subtypes (Gotti et al., 2006a; Quik et al., 2005) . A search for more selective agents that discriminate between these subtypes led to the development of α-CtxMII E11A, in which the glutamic acid at position 11 is replaced with alanine . Oocyte expression studies showed that E11A blocked chimeric α6/α3β2 receptors with ~50 fold lower IC 50 than α3β2 nAChRs . These data suggested that the use of E11A together with 125 I-α-CtxMII may allow for a clearer measure of α6β2* nAChR subtypes in monkey and human striatum.
Our objective was therefore to investigate striatal α6β2* nAChR expression using this novel α-CtxMII analog. Unexpectedly, we observed that E11A discriminated between a very high and high affinity α6β2* nAChR population in mouse striatum. Further studies also demonstrated the presence of two α6β2* nAChR populations in striatum of monkeys and humans. We next investigated how these subtypes were altered with nigrostriatal damage. The results of lesion studies, coupled with experiments using α4 nAChR null mutant mice, suggest there is a preferential loss of the α6α4β2β3 compared to the α6β2β3 nAChR subtype with nigrostriatal damage.
Materials and Methods
Mouse treatment. Ten to twelve-week old male C57BL/6 mice were purchased from Simonsen Laboratories (Gilroy, CA, USA). They were housed in a temperature-controlled room with a 13-h/11-h light/dark cycle in groups of three or four per cage, and had free access to food and water. Four days after arrival, unlesioned mice were administered saline. Lesioned mice were given MPTP (10 mg/kg every 2 h 3-4x for 1 d, or 10-20 mg/kg 2x weekly for 3 wk) to
This article has not been copyedited and formatted. The final version may differ from this version. arrival, monkeys were quarantined for 1 month according to California State regulations. They were housed in a room with a 13-h/11-h light/dark cycle, and given food once daily with water ad libidum. After quarantine, the monkeys were treated with saline (n = 6) or MPTP (n = 8).
MPTP was injected subcutaneously at a dose of 1.5 to 2.0 mg/kg once monthly from 1 to 3 times for cumulative doses of 3.0 to 5.6 mg/kg. Parkinsonism was rated during week four after MPTP injection using a modified Parkinson rating scale for the squirrel monkey (Langston et al., 2000) . The disability scores ranged from 0 to 24 for a severely parkinsonian animal. The composite score was evaluated by an assessment of (1) spatial hypokinesia (reduction in use of the available cage space), (2) body bradykinesia (increased slowness in body movement),
manual dexterity (left and right), (4) balance and (5) freezing. Each parameter was evaluated using a 5-point range with 0 being normal. The monkeys in the lesion 1 group had a score of 5.5 + 3.2, and in the lesion 2 group had a score of 9.6 + 1.9. The monkeys were euthanized ~1 month after the last MPTP injection according to the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. This was done by injecting 1.5 ml euthanasia solution intraperitoneally (390 mg sodium pentobarbital and 50 mg phenytoin sodium/ml), followed by 1.5 ml/kg of the same solution administered intravenously. All studies were performed according to the NIH Guide for the Care and Use of Laboratory Animals, and were approved by the Institutional Animal Care and Use Committee at the Parkinson's Institute.
The brains were then removed, rinsed in saline and divided along the midline. One half of the brain was placed in a mold and cut into 6 mm thick blocks. These were immediately frozen in isopentane on dry ice and stored at -80 o C. Sections (20 µm) were cut from these blocks using a cryostat, mounted on Superfrost Plus TM slides, air dried and stored at -80 o C for further use. The squirrel monkey atlas (Emmers and Akert, 1963) sectioning ranged from A12.0 to A9.5. A previous study from our laboratory had shown that there were no significant anterior-posterior differences in nicotinic receptor or dopamine transporter expression in control or MPTP-lesioned squirrel monkey, in contrast to well documented medial to lateral gradients (Quik et al., 2002) .
Human brain tissue.
Parkinson's disease (n = 4) and control cases (n = 5) were obtained from the brain bank at the Parkinson's Institute and from the Institute for Brain Aging and
Dementia at the University of California, Irvine ( 
I-α-CtxMII autoradiography.
125 I-α-CtxMII (specific activity 2200 Ci/mmol) was prepared as described (Whiteaker et al., 2000) and binding performed as reported earlier (Quik et al., 2004; Quik et al., 2001 ). Competition studies (1.0 fM to 0.1 µM) were done using α-CtxMII or α-CtxMII E11A, which was prepared according to a previous report .
Sections were preincubated at room temperature for 15 min in binding buffer (144 mM NaCl, 1.5 mM KCl, 2 mM CaCl 2 , 1 mM MgSO 4 , 20 mM Hepes, 0.1% BSA, pH 7.5) plus 1 mM phenylmethylsulfonyl fluoride. This was followed by a 1 h incubation at room temperature in binding buffer plus 0.5% BSA, also containing 5 mM EDTA, 5 mM EGTA, and 10 µg/ml each of aprotinin, leupeptin, pepstatin A, and 0.5 nM 125 I-α-CtxMII. To terminate the assay, slides were washed for 10 min in buffer at room temperature followed by 10 min in ice-cold binding buffer, two x 10 min in 0.1x buffer (0°C) and two 5 s washes in water (0°C Table 2 ). The very high affinity site represented 43% and 57%, respectively, of the total E11A-sensitive 125 I-α-CtxMII binding sites (Table 2) . These combined data suggest that the α-CtxMII analog E11A distinguishes between two different α6β2* forms in unlesioned mouse striatum, while α-CtxMII does not.
Preferential loss of the very high affinity α6β2* nAChR subtype in striatum from α4 nAChR null mutant mice. Previous studies had suggested that there were two major α6β2* nAChR in mouse striatum, the α6α4β2β3 and α6β2β3 subtype (Salminen et al., 2004) . As an approach to investigate whether these may be the ones distinguished by E11A, 125 I-α-CtxMII binding was done with varying concentrations of E11A using striatal tissue from α4 nAChR null mutant mice that do not express the α6α4β2β3 nAChR subtype. In contrast to the biphasic 125 I-α-CtxMII competition curves obtained with E11A using striatum from wildtype mice, monophasic curves were observed in striatum of α4 nAChR null mutant mice ( Fig. 2A , Table 2 ).
There appeared to be a preferential loss of the very high affinity component (possibly α6α4β2β3 receptors), with the residual receptor sites more closely resembling the high affinity site (possibly α6β2β3 receptors) in wildtype mice.
Preferential decline in the very high affinity α6β2* nAChR subtype in MPTP-lesioned mouse striatum. To evaluate the extent of nigrostriatal damage, dopamine transporter binding was done on sections from control and MPTP-treated mice (Table 3) . Because some mice were less severely lesioned than others, the data from the animals was divided into two groups, those with moderate (mouse-lesion 1) and those with more severe (mouse-lesion 2) nigrostriatal degeneration ( Table 3 ). The 125 I-α-CtxMII binding values for the mice in these two groups were 69 + 0.4% (n = 4) and 38 + 5.6% (n = 5), respectively, compared to unlesioned mice (Fig. 2B ).
These declines in 125 I-α-CtxMII binding correlated well with those in the dopamine transporter (r = 0.93, p < 0.001), consistent with a previous report (Quik et al., 2003) . 125 I-α-CtxMII binding values in unlesioned mice were 3.15 + 0.06 (n = 8) fmol/mg tissue.
To determine how lesioning affected the two α6β2* binding components defined with E11A, 125 I-α-CtxMII binding was done in the presence of varying concentrations of the analog in striatal tissue from MPTP-treated mice (Fig. 2B ). In the mouse-lesion 1 group, E11A inhibited 125 I-α-CtxMII binding in a biphasic manner similar to that in unlesioned mice, yielding a very high (IC 50 1 = 0.14 pM) and a high (IC 50 2 = 14 pM) affinity binding site ( Fig. 2B ; Table 2 ). With more severe lesioning, the two binding sites could no longer be distinguished with E11A, with the IC 50 intermediate between that of the original very high and high affinity binding site.
α-CtxMII E11A discriminates between α6β2* nAChR subtypes in unlesioned monkey striatum. We next investigated the effect of the α-CtxMII analog E11A on 125 I-α-CtxMII binding and compared the results to those obtained using unlabeled native α-CtxMII in striatum of monkeys (Fig. 3 ). This species offers the advantage that ~50% of the nAChRs in striatum are of the α6β2* subtype, whereas in mice they comprise only ~15% of the total nAChR population (Kulak et al., 2002b) . Consistent with previous results (Quik et al., 2001) , α-CtxMII inhibition of 125 I-α-CtxMII in medial caudate yielded a curve that best fit to a one-site model with an IC 50 = ~230 pM (Table 4 ). In contrast, E11A inhibited 125 I-α-CtxMII binding in medial caudate in a biphasic manner (Fig. 3B) . Two sites were identified with an IC 50 of 9.7 fM and 51 pM, that is, a 5,300 fold difference in affinity between the two α6β2* nAChR populations ( discriminates between at least two α6β2* nAChR subtypes in unlesioned monkey striatum, while α-CtxMII interacts similarly with these two populations.
Preferential decline of the very high affinity E11A-sensitive 125 I-α-CtxMII binding site in striatum of monkeys with nigrostriatal damage. Experiments were done to study receptor changes in striatum of monkeys with nigrostriatal damage. The animals were divided into two groups based on measurement of the dopamine transporter, which yielded a set of monkeys with less severe (monkey-lesion 1) and another more severe (monkey-lesion 2) declines in 125 I-RTI-121 binding (Table 2 ). There were corresponding losses in striatal 125 I-α-CtxMII binding in the two lesioned monkey groups (Fig. 4) , consistent with a previous study (Quik et al., 2001 ). Competition of 125 I-α-CtxMII binding by E11A in striatum of either lesioned group yielded curves that best fit to a one-site model (Table 5) for all striatal regions, that is, medial caudate, lateral caudate, ventral putamen and dorsal putamen. The IC 50 values of the monophasic curves were more similar to those of the high affinity than the very high affinity sites (Table 5 ). These data suggest that there is selective loss of the very high affinity E11A-sensitive 125 I-α-CtxMII
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Competition of 125 I-α-CtxMII binding by α-CtxMII and E11A was initially performed using striatal sections from control human brain (Fig. 5) . Unlabeled α-CtxMII completely displaced 125 I-α-CtxMII binding at 100 nM in both caudate and putamen of control human cases.
Inhibition by native α-CtxMII was monophasic (best fit to a single site), as previously shown (Quik et al., 2004) , with IC 50 values of ~367 pM and ~392 pM in caudate and putamen, respectively ( Fig. 5B ). On the other hand, competition of 125 I-α-CtxMII binding by E11A was biphasic in both the caudate and putamen. There was >500 fold difference in IC 50 between a very high and high affinity 125 I-α-CtxMII binding site, with a roughly similar proportion of sites in each population (Fig. 5B , Table 7 ). These results indicate the presence of at least two E11A-sensitive α6β2* subtypes in human striatum, similar to results in mouse and monkey. To determine whether a select striatal α6β2* subtype was lost, 125 I-α-CtxMII inhibition studies were done with E11A (Fig. 6 , 
Discussion
Results from molecular, pharmacological and functional studies show that the striatum expresses multiple nAChR subunits, which combine to form distinct ligand-gated ion channels (Gotti et al., 2006c; Wonnacott et al., 2005) . These are generally heteromeric and consist of different combinations of α and β subunits, except for α7 nAChRs that are homomeric.
Immunoprecipitation studies with subunit-directed antibodies show that rodent striatum expresses primarily α4, α5, α6, α7, β2, and β3 subunits (Champtiaux et al., 2003; Zoli et al., 2002) . Although the presence of these multiple subunits has the potential to result in a vast array of pentameric nAChRs, the number of subtypes appears fairly limited with the major populations being α4α6β2β3, α6β2β3, α4β2 and α4α5β2 nAChRs (Champtiaux et al., 2003; Gotti et al., 2006b; Salminen et al., 2004; Whiteaker et al., 2002; Zoli et al., 2002) . Primate striatum (nonhuman and human) appears to express a slightly different repertoire of nAChR subunits, including α2, α3, α4, α6, α7, β2 and β3 (Gotti et al., 2006a; Gotti et al., 2006c; Quik et al., 2005) . Receptor subtypes that have been identified to date include α4β2* and α6β2* in both human and monkey striatum, as well as α4α6β2* and α3β2* in the monkey.
As mentioned earlier, 125 I-α-CtxMII has proved to be a very useful ligand to study α6β2* expression and regulation in mice and rats (Quik and McIntosh, 2006 CtxMII also binds to α3β2* nAChRs in human and monkey striatum, results are less clear cut in these latter species (Gotti et al., 2006a; Quik et al., 2005) . The use of the α-CtxMII analog E11A therefore appeared appropriate since it discriminates between the α3β2* and α6β2* subtypes . In oocytes expression studies, 1.0 nM E11A completely inhibited function of chimeric α6/α3β2 nAChRs, while α3β2 receptor-mediated activity was blocked only with ~100 nM of the analog . The present results show that 1.0 nM E11A completely inhibited striatal 125 I-α-CtxMII binding (0.5 nM). These combined findings suggest that radiolabeled 125 I-α-CtxMII binds to α6β2* nAChRs in monkey and human striatum. It is possible that differences in binding affinity between these subtypes in striatum are not as great as the functional differences. However, previous work has shown that the IC 50 for inhibition of 125 I-α-CtxMII binding by E11A in rat striatum was similar to a block of striatal dopamine release, as well as to inhibition of nicotinic receptor-mediated responses in oocytes, at least for the high affinity site which had been detected in earlier studies (Azam and McIntosh, 2005; . Receptor studies in oocytes examining the affinity of E11A for heterologously expressed α3β2* and α6β2* nAChRs may provide a more direct approach to address this issue.
However, receptor detection may be difficult in this system because of low receptor expression and/or high nonspecific binding.
Subsequent competition studies using 125 I-α-CtxMII unexpectedly showed that E11A discriminated between a very high (fM) and high affinity (pM) α6β2* nAChR population in striatum of mice, as well as monkeys and humans. Since mice do not express the α3 nAChR subunit, these two binding sites most likely represent two different α6β2* subtypes, possibly the previously identified α4α6β2β3 and α6β2β3 receptors (Salminen et al., 2004; Zoli et al., 2002) .
This idea is supported by results using α4 knockout mice, in which the α6α4β2β3 subtype is This article has not been copyedited and formatted. The final version may differ from this version. (Quik et al., 2005) .
The differential interaction of E11A with the α4α6β2β3 and α6β2β3 subtypes may arise as a result of different molecular configurations of the α6-β2 interfaces in the two receptor complexes. For instance, in the α6β2β3 receptor there are two α6-β2 interfaces, whereas in the α4α6β2β3 subtype the α6-β2 interface is adjacent to an α4-β2 interface that may affect binding of E11A at the α6-β2 recognition site. Another possibility is that the very high and high affinity components are variably post-translationally modified, that is, phosphorylated or glycosylated.
Such molecular modifications may alter binding such that E11A differentially recognizes the two α6β2* subtypes.
The very high affinity site varied in IC 50 value across species with monkey > mouse > human, while the high affinity site followed the rank order mouse > human > monkey. The divergence in IC 50 values between the two α6β2* subtypes in the same species also differed and ranged from several hundred fold in mouse and human striatum, to several thousand fold in monkey striatum. A possible explanation for the diversity in subtype affinities in various species may relate to differential post-translational modifications of the receptor that affect binding of α- Nigrostriatal damage decreases α6β2* nAChRs in experimental animal models and in
Parkinson's disease (Bohr et al., 2005; Quik et al., 2004; Quik et al., 2001; Quik et al., 2003) .
Moreover, the receptor declines are similar although not identical to those of other dopaminergic markers, suggesting that α6β2* nAChRs are primarily localized to striatal dopaminergic terminals. It was therefore of interest to determine how the very high and high α6β2* components were altered with a nigrostriatal lesion. The very high affinity α6β2* population was the one primarily decreased with moderate lesioning, while the high affinity component was affected only with a more severe lesion. These data, coupled with the results from the α4 nAChR null mutant mice, suggest that dopaminergic terminals expressing the very high affinity α6α4β2β3 nAChR population may be more susceptible to nigrostriatal degeneration. Studies with 125 I-α-CtxMII E11A are required to address this possibility; however, radiolabeled toxin is currently not available.
There is precedence in the literature for the concept that select dopaminergic neuron populations are more readily affected by neurodegenerative insults. Fiber tracts in the substantia nigra differentially project to different striatal areas that appear morphologically distinct (Gerfen et al., 1987b; Langer and Graybiel, 1989) . These dopaminergic afferents show a variable susceptibility to nigrostriatal damage. Identification of the molecular markers linked to this differential depletion may provide insight about the mechanisms responsible for the nigrostriatal neurodegeneration. Indeed, it has been suggested that calbindin is positively linked to nigrostriatal dopamine neuron survival (Gerfen et al., 1987a; German et al., 1992; Liang et al., 1996) whereas neuromelanin has been negatively associated (Herrero et al., 1993; Hirsch et al., 1988; McCormack et al., 2004; Zecca et al., 2003) , although a definitive association of either of This article has not been copyedited and formatted. The final version may differ from this version. Further studies are required to address this possibility.
In summary, the present results are the first to demonstrate the presence of two α6β2* nAChRs populations in striatum of mice, monkeys and humans, which were distinguished using the novel α-CtxMII analog E11A. With respect to their subunit composition, studies with α4 nAChR null mutant mice suggest these two populations represent α6α4β2β3 and α6β2β3 TABLE 2 Loss of the very high α6β2* nAChR subtype in striatum of α4 nAChR null mutant mice and striatum of severely lesioned mice
Results of 125 I-α-CtxMII competition studies by E11A in striatum from wildtype and α4 nAChR null mutant mice (-/-) (experiment 1). Biphasic inhibition curves were obtained using striatum from wildtype mice, with monophasic curves using tissue from α4 nAChR null mutant mice.
The results in experiment 2 are from mice injected with saline or MPTP. The MPTP-lesioned mice were divided into two groups based on the extent of loss of striatal 125 I-α-CtxMII binding sites (lesion 1 and lesion 2). Biphasic inhibition curves were observed for unlesioned mice, and mice with less severe declines in 125 I-α-CtxMII binding (lesion 1). In contrast, monophasic curves were obtained using striatum from severely lesioned mice (lesion 2 
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